share_log
Moomoo 24/7 ·  Apr 9 16:34
Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment